Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) )

Avadel pharmaceuticals provides corporate update and reports second quarter 2021 financial results

Dublin, ireland, aug. 09, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (eds) and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the second quarter ended june 30, 2021.
AVDL Ratings Summary
AVDL Quant Ranking